Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Outlook Therapeutics's price to sales ratio was 3.2× on Jan 31, 2020, against 17.9× a year earlier. Over the last 3 years it ranged from 2.1× to 32.9×, with a median of 13.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Jan 31, 2020 | 3.2× | +1.2 |
| 2019 | Dec 31, 2019 | 2.1× | −9.6 |
| 2018 | Dec 31, 2018 | 11.7× | +3.2 |
| 2017 | Dec 29, 2017 | 8.5× | −14.5 |
| 2016 | Dec 30, 2016 | 23.0× | – |
See a number that looks wrong?